Clinical Trials Browser

Interventional × futibatinib × Gastrointestinal × Clear all

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05727176 2025-12-29

FOENIX-CCA4

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04828486 2025-11-18

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Phase 2 Terminated

115 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part